[go: up one dir, main page]

WO2012041761A3 - Botulinum neurotoxin polypeptides exhibiting a prolonged activity - Google Patents

Botulinum neurotoxin polypeptides exhibiting a prolonged activity Download PDF

Info

Publication number
WO2012041761A3
WO2012041761A3 PCT/EP2011/066504 EP2011066504W WO2012041761A3 WO 2012041761 A3 WO2012041761 A3 WO 2012041761A3 EP 2011066504 W EP2011066504 W EP 2011066504W WO 2012041761 A3 WO2012041761 A3 WO 2012041761A3
Authority
WO
WIPO (PCT)
Prior art keywords
polynucleotide
neurotoxin
botulinum neurotoxin
neurotoxin polypeptide
polypeptides exhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2011/066504
Other languages
French (fr)
Other versions
WO2012041761A2 (en
Inventor
Juergen Frevert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merz Pharma GmbH and Co KGaA
Original Assignee
Merz Pharma GmbH and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma GmbH and Co KGaA filed Critical Merz Pharma GmbH and Co KGaA
Publication of WO2012041761A2 publication Critical patent/WO2012041761A2/en
Publication of WO2012041761A3 publication Critical patent/WO2012041761A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

The present invention pertains to the field of modified neurotoxin polypeptides. In particular, it relates to a polynucleotide encoding a neurotoxin polypeptide comprising at least two neurotoxin light chains and a heavy chain. The neurotoxin polypeptide encoded by the polynucleotide exhibits, in an aspect, a prolonged duration of the biological effect in a subject. Moreover, contemplated are a vector and a host cell which comprise the polynucleotide as well as a neurotoxin polypeptide encoded by the aforementioned polynucleotide. Further, the present invention relates to a medicament comprising the polynucleotide, the vector or the neurotoxin polypeptide and its therapeutic and cosmetic applications.
PCT/EP2011/066504 2010-09-28 2011-09-22 Botulinum neurotoxin polypeptides exhibiting a prolonged activity Ceased WO2012041761A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US40416610P 2010-09-28 2010-09-28
EP10181374 2010-09-28
US61/404,166 2010-09-28
EP10181374.9 2010-09-28

Publications (2)

Publication Number Publication Date
WO2012041761A2 WO2012041761A2 (en) 2012-04-05
WO2012041761A3 true WO2012041761A3 (en) 2012-08-16

Family

ID=43302480

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2011/066504 Ceased WO2012041761A2 (en) 2010-09-28 2011-09-22 Botulinum neurotoxin polypeptides exhibiting a prolonged activity

Country Status (1)

Country Link
WO (1) WO2012041761A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10792344B2 (en) * 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
JP7158371B2 (en) * 2016-07-08 2022-10-21 ザ チルドレンズ メディカル センター コーポレーション Novel botulinum neurotoxin and its derivatives
EP3641746B1 (en) * 2017-06-19 2024-11-20 President And Fellows Of Harvard College Methods and compositions for treating a microbial infection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022979A1 (en) * 2008-08-29 2010-03-04 Merz Pharma Gmbh & Co. Kgaa Clostridial neurotoxins with altered persistency

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010022979A1 (en) * 2008-08-29 2010-03-04 Merz Pharma Gmbh & Co. Kgaa Clostridial neurotoxins with altered persistency

Also Published As

Publication number Publication date
WO2012041761A2 (en) 2012-04-05

Similar Documents

Publication Publication Date Title
MX352265B (en) Neurotoxins exhibiting shortened biological activity.
HK1207665A1 (en) Polypeptides having transgalactosylating activity
MX2014005544A (en) Neurotoxins exhibiting shortened biological activity.
IN2014DN05670A (en)
WO2011123683A3 (en) Protease activated cytokines
WO2013102144A3 (en) Ph20 polypeptide variants, formulations and uses thereof
WO2012069655A3 (en) Improved capping modules for designed ankyrin repeat proteins
IL294314A (en) Fibronectin based scaffold domain proteins that bind to myostatin
IL244154A0 (en) Botulinum neurotoxin for use in treating depression
WO2013006953A8 (en) Genes and proteins for alkanoyl-coa synthesis
WO2013040093A3 (en) Glucagon-like peptide-2 compositions and methods of making and using same
WO2012167901A3 (en) Cosmetic and dermatological photoprotective preparation with improved water resistance
MD20140104A2 (en) CX3CR1-binding polypeptides
WO2010034718A8 (en) Recombinant proteins having haemostatic activity and capable of inducing platelet aggregation
WO2015048498A3 (en) Carrier-free biologically-active protein nanostructures
EP4582090A3 (en) Composition comprising pegylated arginine deiminase
PH12012501831A1 (en) Protein ipa1 related to plant architecture, its coding genes and uses
WO2016022377A3 (en) Methods for modulating the glycosylation profile of recombinant proteins using dissolved oxygen
BR112015008673A2 (en) compound, pharmaceutical composition and method
WO2012048171A3 (en) Variant cbh i polypeptides with reduced product inhibition
EP2638152A4 (en) RECOMBINANT BETA-GLUCOCEREBROSIDASE PROTEINS, VARIANTS, HAVING INCREASED STABILITY AND INCREASED CATALYTIC RESIDUAL ACTIVITY
MX2011004483A (en) Leukolectins and uses thereof.
WO2013169631A3 (en) Wnt protein signalling inhibitors
WO2012101156A3 (en) Human lactoferrin based peptides having antiinflammatory activity
MX2021002985A (en) Short-acting factor vii polypeptides.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11761341

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11761341

Country of ref document: EP

Kind code of ref document: A2